Medco Announces Two-For-One Stock Split(ormation that is critical to the o...),Health

operation of our business;

-- Our specialty pharmacy business is dependent on our relationships with

a limited number of biopharmaceutical suppliers and the loss of any of

these relationships could significantly impact our ability to sustain

or increase our revenues;

-- Our ability to grow our specialty pharmacy business could be limited if

we do not expand our existing base of drugs or if we lose patients;

-- Our specialty pharmacy business and Medicare Part D offerings expose us

to increased credit risk;

-- Changes in industry pricing benchmarks could adversely affect our

financial performance;

-- The terms and covenants relating to our existing indebtedness could

adversely impact our financial performance;

-- Prescription volumes may decline, and our net revenues and

profitability may be negatively impacted, if products are withdrawn

from the market or if increased safety risk profiles of specific drugs

result in utilization decreases;

-- We may be subject to liability claims for damages and other expenses

that are not covered by insurance;

-- The success of our business depends on maintaining a well-secured

pharmacy operation and technology infrastructure and failure to execute

could adversely impact our business;

-- We could be required to record a material non-cash charge to income if

our recorded intangible assets are impaired, or if we shorten

intangible asset useful lives; and,

-- Anti-takeover provisions of the Delaware General Corporation Law

("DGCL"), our certificate of incorporation and our bylaws could delay

or deter a change in control and make it more difficult to remove

incumbent officers and directors.

The foregoing list of factors is not exhaustive. You should carefully consider the
'/>"/>